Exploring How to Enhance Drug Delivery and Efficacy Through Nanoparticles and Macroscale Materials

Micrograph of a hydrogel, nanoparticle for gene delivery, and microneedle patch

Natalie Artzi, PhD, a principal investigator in the Brigham and Women’s Hospital Department of Medicine, has changed our basic understanding of biomaterials under different environmental and pathological states. Her lab is dedicated to designing smart biomaterial platforms and medical devices to improve human health.

Read More...

Pushing the Boundaries of Research and Clinical Care in Pancreatic Cancer

From novel laboratory research that enables scientists to define pancreatic cancer cells better to new clinical approaches that expedite postsurgical recovery, Dana-Farber Brigham Cancer Center is steadily advancing the diagnosis and management of pancreatic cancers. Sahar Nissim, MD, PhD, and Thomas E. Clancy, MD, FACS, elaborate.

Read More...

Researchers Discover Role of PD-1 in Driving Growth of Merkel Cell Carcinoma

In a study published in Science Advances, investigators reported for the first time that Merkel cell carcinoma cells express programmed cell death 1 (PD-1). This research has crucial implications for the potential development of new combination therapies for the disease, as senior author Tobias Schatton, PharmD, PhD, explains.

Read More...

Meet Anthony D’Amico, MD, PhD

Anthony D'Amico MD, PhD

Meet Anthony D’Amico, MD, PhD, Chief of Genitourinary Radiation Oncology at Dana-Farber Brigham Cancer Center, and Eleanor Theresa Walters Distinguished Chair in Radiation Oncology, renowned for his exceptional contributions to cancer care, particularly in genitourinary cancer.

Read More...

Patients With EGFR-Mutant NSCLC May Benefit from Targeted Therapy More Than Checkpoint Inhibitors

An estimated 10 to 15% of non-small cell lung cancers harbor EGFR mutations.

A recent retrospective, multicenter cohort study suggests osimertinib is more likely to benefit non-small cell lung cancer patients with EGFR mutations than alternative approaches, though prospective clinical trials are needed to confirm the findings. The Brigham’s Elio Adib, MD, a co-author of the study, discusses key takeaways.

Read More...

Gene Therapy Approach Shows Encouraging Survival Results in Some Patients With Glioblastoma

In a first-in-human, phase 1 trial, Brigham researchers sought to address challenges associated with treating glioblastoma multiforme by using an injected, engineered oncolytic virus that activated immune cells in the tumor. E. Antonio Chiocca, MD, PhD, senior author of the paper, recently presented the study findings.

Read More...

Advancing AI to Help Predict, Diagnose, Treat, and Address Equity Issues in Cancer

Brigham and Women’s Hospital and Dana-Farber Cancer Institute radiologists and radiation oncologists are at the forefront of harnessing the power of AI to change patients’ lives, as reflected in several recent research projects. Learn about the work of Michael H. Rosenthal, MD, PhD, Benjamin H. Kann, MD, Martin T. King, MD, PhD, and Danielle S. Bitterman, MD.

Read More...

New Study Highlights Dangers of Patients Relying on ChatGPT for Treatment Recommendations

Danielle S. Bitterman, MD, is the corresponding author of a study that assessed the ability of ChatGPT to recommend guidelines-based cancer treatments. She and her colleagues found the chatbot provided inappropriate recommendations in about one-third of cases, indicating the need to raise awareness about its limitations.

Read More...

Meet Adam Kibel, MD, Newly Appointed Chair of the Department of Urology

Meet Adam Kibel, MD, the newly appointed chair of the new Department of Urology at Brigham and Women’s Hospital and Disease Center Leader, Urology at Dana-Farber Brigham Cancer Center.

Read More...

Biomarker-Based Surveillance Holds Promise for HPV-Positive Oropharynx Cancer, But Caution Is Urged

Oropharyngeal squamous cell carcinoma is growing in incidence and now seen primarily in patients with human papillomavirus (HPV). Eleni M. Rettig, MD, associate surgeon at the Brigham, recently published a review of a biomarker-based surveillance method that includes a plasma-based assay to detect circulating tumor HPV DNA post-treatment.

Read More...